Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Rises By 38.4%

Palisade Bio, Inc. (NASDAQ:PALI) was the recipient of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 148,000 shares, an increase of 38.4% from the February 13th total of 106,900 shares. Based on an average daily volume of 1,480,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 5.4% of the shares of the company are sold short.

Palisade Bio Stock Down 13.3 %

PALI stock traded down $0.13 during trading on Monday, reaching $0.87. 380,763 shares of the company’s stock were exchanged, compared to its average volume of 757,491. The company’s fifty day moving average price is $1.27 and its 200-day moving average price is $2.29. The firm has a market cap of $2.40 million, a PE ratio of -0.06 and a beta of 1.49. Palisade Bio has a 1-year low of $0.75 and a 1-year high of $9.65.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Palisade Bio stock. JPMorgan Chase & Co. purchased a new position in Palisade Bio, Inc. (NASDAQ:PALI) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned approximately 0.54% of Palisade Bio at the end of the most recent quarter. Institutional investors and hedge funds own 11.79% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Brookline Capital Management began coverage on shares of Palisade Bio in a report on Wednesday, November 20th. They issued a “buy” rating and a $38.00 target price on the stock.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.